About Kalder
Built with a long-term pharmaceutical vision.
Our Story
Why we are building Kalder.
Kalder Pharmaceuticals was founded with the idea that pharmaceutical distribution can be operated more efficiently by combining disciplined supply-chain practices with modern technology.
The company is beginning with an asset-light pharmaceutical distribution model — using a qualified pharmaceutical 3PL for physical warehousing and fulfillment while building the technology, supplier relationships, and customer network in-house.
Distribution is the entry point, not the final destination. The infrastructure, data, and relationships built in Phase 1 will serve as the foundation for future owned products and eventually pharmaceutical manufacturing.
Mission
Improve the pharmaceutical supply chain through reliable distribution, disciplined operations, and modern technology.
Vision
Build a vertically integrated, technology-driven pharmaceutical company connecting distribution, product ownership, manufacturing, and healthcare supply through one modern operating platform.
How We Operate
Our Operating Principles
Quality before speed
Compliance and product integrity are never traded for operational convenience.
Compliance before convenience
Regulatory obligations shape how we operate, not work around how we prefer to.
Data before guesswork
Every purchasing, pricing, and inventory decision is informed by structured data.
Sustainable growth before unnecessary scale
We build for the long term, not for the appearance of growth.
Long-term relationships over transactions
Customers and suppliers are strategic partners, not single-order opportunities.
Technology reduces friction
Software should make operations more reliable and accountable — not replace accountability.
Long-Term Roadmap
Distribution is the first chapter.
Phase 1 — Current
Lean Pharmaceutical Distribution
Launch a compliant, asset-light distribution business using a qualified pharmaceutical 3PL, building supplier and customer relationships.
Phase 2
Private-Label & Owned OTC Products
Introduce selected owned products through qualified contract manufacturers to increase gross margins and brand equity.
Phase 3
Owned Generic Prescription Products
Develop, acquire, license, or partner around generic drug products and regulatory approvals.
Phase 4
Complex & Specialty Generics
Move toward products with greater technical barriers, stronger economics, and deeper market differentiation.
Phase 5
Pharmaceutical Manufacturing
Build, acquire, or partner around pharmaceutical manufacturing when product demand and capital justify vertical integration.
Interested in partnering with Kalder?
We are actively building supplier, customer, and logistics relationships ahead of launch.
Start a Conversation